New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
08:01 EDTZGNXZogenix price target lowered to $3.50 from $5 at Stifel
Stifel cut its price target on Zogenix after the company solid its primary revenue line, Sumavel DosePro, to Endo (ENDP). Stifel applauds the sale of the product as the firm thinks it was challenging for Zogenix to sell. The firm thinks the company's performance should improve, as it is upbeat about the outlook for the company's first abuse deterrent formulation. The firm keeps a Buy rating on the shares.
News For ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ZGNX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use